Anales de la RANM

232 A N A L E S R A N M R E V I S T A F U N D A D A E N 1 8 7 9 MAGNESIO E INHIBIDORES DE SGLT2 Riaza Ortiz C, et al. An RANM. 2025;142(03): 226 - 232 8. Yap YG, Camm AJ. Drug induced QT pro- longation and torsades de pointes. Heart. 2003;89(11):1363-1372. doi: 10.1136/ heart.89.11.1363. 9. Vart P. From Kidney to Heart - and Beyond - SGLT2 Inhibitors in Chronic Kidney Disease. NEJM Evid. 2025;4(11):EVIDe2500255. doi: 10.1056/EVIDe2500255. 10. Diker Cohen T, Polansky A, Bergman I, et al. Safety of sodium-glucose cotranspor- ter 2 inhibitors in kidney transplant reci- pients with diabetes mellitus. Diabetes Metab 2025;51(3):101627, doi: 10.1016/j.diabet.2025. 11. Sánchez Fructuoso AI, Bedia Raba A, Banegas Deras E, et al. Sodium-glucose cotranspor- ter-2 inhibitor therapy in kidney transplant patients with type 2 or post-transplant diabe- tes: an observational multicentre study. Clin Kidney J 2023;16(6):1022-1034. doi: 10.1093/ ckj/sfad007. 12. Secondulfo C, Vecchione N, Russo D, et al. Impact of SGLT2 Inhibitors on Magnesium in Kidney Transplant Patients with and Without Diabetes. Int J Mol Sci 2025; 26(7):2904. doi: 10.3390/ijms26072904. 13. Song CC, Brown A, Winstead R, et al. Early ini- tiation of sodium-glucose linked transporter inhibitors (SGLT-2i) and associated metabolic and electrolyte outcomes in diabetic kidney transplant recipients. Endocrinol Diabetes Me- tab 2020; 4(2):e00185. doi: 10.1002/edm2.185. 14. Zhang J, Huan Y, Leibensperger M, Seo B, Song Y. Comparative Effects of Sodium-Glucose Co- transporter 2 Inhibitors on Serum Electroly- te Levels in Patients with Type 2 Diabetes: A Pairwise and Network Meta-Analysis of Ran- domized Controlled Trials. Kidney360 2022; 3(3):477-487. doi: 10.34067/KID.0006672021. 15. Osawa K, Ohya M, Yamamoto S, et al. SGLT2 inhibitors increase low serum magnesium le- vels in patients with chronic kidney disease immediately after treatment. Clin Exp Nephrol 2025; 29(4):452-459. doi: 10.1007/s10157-024- 02590-8. 16. Mahalwar G, Mathew RO, Rangaswami J. Sodium-glucose cotransporter 2 inhibi- tors and cardiorenal outcomes in kidney transplantation. Curr Opin Nephrol Hy- perten. 2024; 33(1):53-60. doi: 10.1097/ MNH.0000000000000948. 17. Cianciolo G, De Pascalis A, Gasperoni L, et al. The Off-Target Effects, Electrolyte and Mineral Disorders of SGLT2i. Molecu- les 2020;25(12):2757. doi: 10.3390/molecu- les25122757 18. Mazer CD, Hare GMT, Connelly PW, et al. Effect of Empagliflozin on Erythropoietin Le- vels, Iron Stores, and Red Blood Cell Morpho- logy in Patients With Type 2 Diabetes Melli- tus and Coronary Artery Disease. Circulation 2020;141(8):704-707. doi: 10.1161/CIRCULA- TIONAHA.119.044235. 19. Heerspink HJL, Stefánsson BV, Correa-Rot- ter R, et al. Dapagliflozin in Patients with Chronic Kidney Disease. N Engl J Med. 2020;383(15):1436-1446. doi: 10.1056/NEJ- Moa2024816. 20. Docherty KF, Curtain JP, Anand IS, et al. Effect of dapagliflozin on anaemia in DAPA- HF. Eur J Heart Fail. 2021; 23(4):617-628. doi: 10.1002/ejhf.2132. Epub 2021 Mar 22. PMID: 33615642; PMCID: PMC11497230. 21. Ekanayake P, Mudaliar S. Increase in hemato- crit with SGLT-2 inhibitors - Hemoconcentra- tion from diuresis or increased erythropoiesis after amelioration of hypoxia? Diabetes Me- tab Syndr. 2023;17(2):102702. doi: 10.1016/j. dsx.2022.102702. 22. Osonoi T, Shirabe S, Saito M, et al. Dapagli- flozin Improves Erythropoiesis and Iron Me- tabolism in Type 2 Diabetic Patients with Renal Anemia. Diabetes Metab Syndr Obes 2023;16:1799-1808. doi: 10.2147/DMSO. S411504. 23. Wang D, Liu J, Zhong L, et al. The effect of sodium-glucose cotransporter 2 inhibitors on biomarkers of inflammation: A systematic re- view and meta-analysis of randomized contro- lled trials. Front Pharmacol 2022;13:1045235. doi: 10.3389/fphar.2022.1045235. 24. Bray JJH, Foster-Davies H, Stephens JW. A systematic review examining the effects of sodium-glucose cotransporter-2 inhibitors (SGLT2is) on biomarkers of inflammation and oxidative stress. Diabetes Res Clin Pract 2020;168:108368. doi: 10.1016/j.dia- bres.2020.108368. 25. Hisadome Y, Mei T, Noguchi H, et al. Safety and Efficacy of Sodium-glucose Cotranspor- ter 2 Inhibitors in Kidney Transplant Reci- pients With Pretransplant Type 2 Diabetes Mellitus: A Retrospective, Single-center, In- verse Probability of Treatment Weighting Analysis of 85 Transplant Patients. Trans- plant Direct 2021;7(11):e772. doi: 10.1097/ TXD.0000000000001228. 26. Kanbay M, Demiray A, Afsar B, et al. Sodium- glucose cotransporter 2 inhibitors for diabetes mellitus control after kidney transplantation: Review of the current evidence. Nephrolo- gy (Carlton) 2021;26(12):1007-1017. doi: 10.1111/nep.13941. Si desea citar nuestro artículo: Riaza Ortiz C, Sánchez Fructuoso AI. Incremento del mag- nesio sérico y efectos metabólicos del tratamiento con inhibidores de SGLT2 en pacientes trasplantados rena- les. An RANM. 2025;142(03): 226– 232. DOI: 10.32440/ ar.2025.142.03. org01